Development and validation of an eating behavior patient‐reported outcome measure in people living with obesity or overweight.
- Published in:
- Obesity (19307381), 2025, v. 33, n. 7, p. 1249, doi. 10.1002/oby.24299
- By:
- Publication type:
- Article
Works by Lucas, Kathryn J.
Results: 4
1
2
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP‐1 receptor dual agonist.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 4, p. 1773, doi. 10.1111/dom.16167
- By:
- Publication type:
- Article
3
Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 993, doi. 10.1111/dom.16052
- By:
- Publication type:
- Article
4
Iodine-131 Metaiodobenzylguanidine Scintigraphy of Carcinoid Tumors.
- Published in:
- Journal of Nuclear Medicine, 1986, v. 27, n. 11, p. 1691
- By:
- Publication type:
- Article